The history of Viagra presents a complex case for investors in the pharmaceutical sector. While initially a tremendous success, producing huge profits, the exclusivity end and the subsequent arrival of off-brand competitors have drastically changed income. This raises questions about the future sustainability of analogous drug developments and sugg